0001415889-24-004781.txt : 20240222 0001415889-24-004781.hdr.sgml : 20240222 20240222160525 ACCESSION NUMBER: 0001415889-24-004781 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240220 FILED AS OF DATE: 20240222 DATE AS OF CHANGE: 20240222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MANNING MARTHA E CENTRAL INDEX KEY: 0001227894 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36576 FILM NUMBER: 24664664 MAIL ADDRESS: STREET 1: 700 PENNSYLVANIA DR CITY: EXTON STATE: PA ZIP: 19341 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MARINUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001267813 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 BUSINESS PHONE: 484-801-4670 MAIL ADDRESS: STREET 1: 5 RADNOR CORPORATE CENTER SUITE 500 STREET 2: 100 MATSONFORD RD CITY: RADNOR STATE: PA ZIP: 19087 FORMER COMPANY: FORMER CONFORMED NAME: MARINUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20031022 4 1 form4-02222024_040201.xml X0508 4 2024-02-20 0001267813 MARINUS PHARMACEUTICALS, INC. MRNS 0001227894 MANNING MARTHA E 5 RADNOR CORPORATE CENTER, SUITE 500 100 MATSONFORD RD RADNOR PA 19087 false true false false SVP, GEN. COUNSEL & CORP. SEC. 0 Common Stock 2024-02-20 4 S 0 1894 9.57 D 52966 D The sales reported on this Form 4 represent shares of common stock of Marinus Pharmaceuticals, Inc. (the "Company") sold by the reporting person pursuant to a Rule 10b5-1 Plan adopted on May 16, 2022 to cover tax obligations in connection with the vesting of restricted stock units. The price reported in column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $9.07 to $9.78, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. /s/ Debra A. Mohollen, Attorney-in-Fact 2024-02-22